CCG
REGN icon

Cypress Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Cypress Capital Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-354
Closed -$372K – 296
2024
Q3 		$372K Buy
354
+3
+0.9% +$3.34K 0.04% 246
2024
Q2 		$369K Sell
351
-41
-10% -$39.7K 0.04% 234
2024
Q1 		$377K Sell
392
-1,010
-72% -$960K 0.05% 235
2023
Q4 		$1.23M Sell
1,402
-10
-0.7% -$8.23K 0.16% 115
2023
Q3 		$1.16M Sell
1,412
-298
-17% -$234K 0.17% 117
2023
Q2 		$1.23M Buy
1,710
+59
+4% +$45.5K 0.18% 121
2023
Q1 		$1.36M Sell
1,651
-13
-0.8% -$9.8K 0.21% 110
2022
Q4 		$1.2M Buy
1,664
+77
+5% +$56.8K 0.18% 120
2022
Q3 		$1.09M Buy
+1,587
New +$999K 0.18% 116
2021
Q1 		– Sell
-713
Closed -$344K – 290
2020
Q4 		$344K Sell
713
-43
-6% -$23.2K 0.05% 230
2020
Q3 		$423K Buy
756
+32
+4% +$19.4K 0.07% 197
2020
Q2 		$452K Buy
724
+189
+35% +$107K 0.08% 179
2020
Q1 		$261K Sell
535
-123
-19% -$50.7K 0.06% 177
2019
Q4 		$247K Buy
+658
New +$221K 0.04% 220
2016
Q1 		– Sell
-868
Closed -$471K – 178
2015
Q4 		$471K Hold
868
– – 0.11% 127
2015
Q3 		$404K Buy
868
+161
+23% +$86.5K 0.1% 146
2015
Q2 		$361K Hold
707
– – 0.08% 160
2015
Q1 		$319K Sell
707
-140
-17% -$59.3K 0.07% 176
2014
Q4 		$347K Buy
847
+140
+20% +$55.1K 0.08% 167
2014
Q3 		$255K Buy
+707
New +$237K 0.06% 187
2014
Q2 		– Sell
-707
Closed -$212K – 213
2014
Q1 		$212K Buy
+707
New +$218K 0.05% 201
2013
Q4 		– Sell
-707
Closed -$221K – 215
2013
Q3 		$221K Buy
+707
New +$186K 0.05% 193

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cypress Capital Group's REGN Position: Q4 2024 in Review

Cypress Capital Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 354 shares — an estimated $372K sold.

Cypress Capital Group first reported a position in REGN in Q3 2013 and held it in 22 quarters. The position peaked at $1.36M in Q1 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Cypress Capital Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Group sold 354 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $372K.
  • Cypress Capital Group first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 22 quarters.
  • Cypress Capital Group's Regeneron Pharmaceuticals position peaked at $1.36M in Q1 2023.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Cypress Capital Group's 13F filing for Q4 2024, filed 6 Feb 2025.